Trials / Completed
CompletedNCT01929655
Japanese BAY88-8223 Monotherapy Phase II Study
A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of the best standard of care plus BAY88-8223 in Japanese patients with CRPC and bone metastases after a multiple administration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223 dichloride (Xofigo, BAY88-8223) | BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration |
Timeline
- Start date
- 2013-09-30
- Primary completion
- 2017-05-16
- Completion
- 2017-05-16
- First posted
- 2013-08-28
- Last updated
- 2018-04-24
Locations
16 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01929655. Inclusion in this directory is not an endorsement.